Literature DB >> 8712226

Heparin-induced thrombocytopenia in hemodialysis patients.

S Yamamoto1, M Koide, M Matsuo, S Suzuki, M Ohtaka, S Saika, T Matsuo.   

Abstract

This study was conducted to determine the incidence of heparin-induced thrombocytopenia (HIT), an important complication in heparin therapy, in 154 hemodialysis patients, with characterization of the subtypes using an enzyme-linked immunosorbent assay. The etiology of the immunologic type of HIT is suggested to involve the binding of a specific antibody for platelet factor 4-heparin complex to platelets and their consequent activation. The 154 consecutive patients were newly treated with hemodialysis due to chronic or acute renal failure between January 1993 and July 1995. Heparin-induced thrombocytopenia was suspected in six patients (3.9%), and its presence was confirmed by platelet aggregation testing. Five of the patients with HIT had anti-platelet factor 4-heparin complex antibody detected by the enzyme-linked immunosorbent assay and were diagnosed with immunologic HIT. The patient who did not have the antibody was thought to have another type of HIT.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8712226     DOI: 10.1016/s0272-6386(96)90134-1

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  22 in total

1.  Low-density lipoprotein apheresis reduces platelet factor 4 on the surface of platelets: a possible protective mechanism against heparin-induced thrombocytopenia and thrombosis.

Authors:  Yvette C Tanhehco; Ann H Rux; Bruce S Sachais
Journal:  Transfusion       Date:  2010-10-26       Impact factor: 3.157

Review 2.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

3.  Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis.

Authors:  Iván Palomo; Jaime Pereira; Marcelo Alarcón; Gonzalo Díaz; Patricia Hidalgo; Isabel Pizarro; Eric Jara; Patricio Rojas; Guillermo Quiroga; Rodrigo Moore-Carrasco
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

Review 4.  Heparin-induced thrombocytopenia: molecular pathogenesis.

Authors:  Seon Ho Lee; Chao Yan Liu; Gian PaoloVisentin
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27

Review 6.  Heparin-induced thrombocytopenia: a renal perspective.

Authors:  Samaha Syed; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

7.  Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C.

Authors:  Chika Nishida; Hirofumi Uto; Makoto Oketani; Koki Tokunaga; Tsuyoshi Nosaki; Mayumi Fukumoto; Manei Oku; Atsushi Sogabe; Akihiro Moriuchi; Akio Ido; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2009-11-05       Impact factor: 7.527

8.  The clinical diagnosis of heparin-induced thrombocytopenia in patients receiving continuous renal replacement therapy.

Authors:  Chris E Holmes; Joe C Huang; Carina Cartelli; Alan Howard; Jeffrey Rimmer; Mary Cushman
Journal:  J Thromb Thrombolysis       Date:  2008-05-17       Impact factor: 2.300

Review 9.  Anticoagulation in CKD and ESRD.

Authors:  Kelvin Cheuk-Wai Leung; Jennifer Marie MacRae
Journal:  J Nephrol       Date:  2019-01-28       Impact factor: 3.902

Review 10.  Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.

Authors:  Jenny I Shen; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2012-05-05       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.